NasdaqGS:GERNBiotechs
Assessing Geron (GERN) Valuation After Q1 2026 Earnings Beat And RYTELO Growth Progress
Geron (GERN) is back in focus after its Q1 2026 earnings, where revenue and loss per share came in ahead of expectations, supported by RYTELO growth, reiterated full-year guidance, and pipeline updates.
See our latest analysis for Geron.
Despite the stronger Q1 update, Geron’s 1-day share price return of a 7.6% decline and 1-month share price return of a 16.1% decline suggest fading near-term momentum, while the 1-year total shareholder return of 15.9% and 3-year total shareholder return of a...